文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

评估水凝胶直肠间隔物在前列腺癌放射治疗中的成本效益

Evaluating the Cost-Effectiveness of Hydrogel Rectal Spacer in Prostate Cancer Radiation Therapy.
PubMed 文献 · Pract Radiat Oncol · 2018-10-17

该研究从美国支付方视角构建多状态马尔可夫模型,比较局部前列腺癌患者接受单纯外照射放疗与联合水凝胶直肠间隔物的成本效益。住院门诊场景下每例5年增量成本为3578美元、增量效果为0.0371质量调整生命年,增量成本效果比为每质量调整生命年96440美元;门诊手术机构场景为每质量调整生命年39286美元。作者结论认为在10万美元支付意愿阈值下间隔物具有成本效益,但结果存在较大不确定性,需要更多证据。

要点

  • 住院门诊置入间隔物每例5年增量成本3578美元,增量效果0.0371质量调整生命年,增量成本效果比96440美元/质量调整生命年。
  • 门诊手术机构置入间隔物增量成本效果比为39286美元/质量调整生命年。
  • 基线勃起功能良好者中,住院门诊与门诊手术机构增量成本效果比分别为35548与9627美元/质量调整生命年。

核心结论

  • 基于现行美国联邦医疗保险医师费用表,在10万美元支付意愿阈值下水凝胶直肠间隔物具有成本效益。
  • 作者指出这些结果包含相当大的不确定性,提示需要更多证据以完善未来决策。

研究设计与样本

  • 从美国支付方视角构建多状态马尔可夫模型,比较局部前列腺癌男性接受单纯外照射放疗与外照射放疗联合水凝胶直肠间隔物的成本效益。
  • 按间隔物置入地点(医院门诊、医师办公室、门诊手术机构)及基线勃起功能良好患者比例进行亚组分析。
  • 勃起功能、胃肠道与泌尿生殖系统毒性发生率及间隔物置入相关潜在风险数据来自近期发表的随机临床试验,健康效用值与成本来自文献及2018年医师费用表,按每年3%贴现,模型时间为自放疗起5年。
  • 进行了概率敏感性分析与价值导向阈值分析。

主要发现

  • 医院门诊场景下每例5年增量成本为3578美元,增量效果为0.0371质量调整生命年。
  • 医院门诊置入间隔物的增量成本效果比为96440美元/质量调整生命年,门诊手术机构置入为39286美元/质量调整生命年。
  • 基线勃起功能良好的男性中,医院门诊与门诊手术机构场景的增量成本效果比分别为35548美元/质量调整生命年与9627美元/质量调整生命年。

关键数值与推荐

  • 医院门诊置入间隔物:每例5年增量成本3578美元,增量效果0.0371质量调整生命年,增量成本效果比96440美元/质量调整生命年。
  • 门诊手术机构置入间隔物:增量成本效果比39286美元/质量调整生命年。
  • 基线勃起功能良好者医院门诊置入:增量成本效果比35548美元/质量调整生命年;门诊手术机构置入:9627美元/质量调整生命年。
  • 成本与健康效用按每年3%贴现,模型时间范围为自放疗起5年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出这些结果包含相当大的不确定性,提示需要更多证据以完善未来决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A hydrogel rectal spacer (HRS) is a medical device that is approved by the U.S. Food and Drug Administration to increase the separation between the prostate and rectum. We conducted a cost-effectiveness analysis of HRS use for reduction in radiation therapy (RT) toxicities in patients with prostate cancer (PC) undergoing external beam RT (EBRT). METHODS AND MATERIALS: A multistate Markov model was constructed from the U.S. payer perspective to examine the cost-effectiveness of HRS in men with localized PC receiving EBRT (EBRT alone vs EBRT + HRS). The subgroups analyzed included site of HRS placement (hospital outpatient, physician office, ambulatory surgery center) and proportion of patients with good baseline erectile function (EF). Data on EF, gastrointestinal and genitourinary toxicities incidence, and potential risks associated with HRS implantation were obtained from a recently published randomized clinical trial. Health utilities and costs were derived from the literature and the 2018 Physician Fee Schedule and were discounted 3% annually. Quality-adjusted life years (QALYs) and costs were modeled for a 5-year period from receipt of RT. Probabilistic sensitivity analysis and value-based threshold analyses were conducted. RESULTS: The per-patient 5-year incremental cost for spacers administered in a hospital outpatient setting was $3578, and the incremental effectiveness was 0.0371 QALYs. The incremental cost-effectiveness ratio was $96,440/QALY for patients with PC undergoing HRS insertion in a hospital and $39,286/QALY for patients undergoing HRS insertion in an ambulatory facility. For men with good baseline EF, the incremental cost-effectiveness ratio was $35,548/QALY and $9627/QALY in hospital outpatient and ambulatory facility settings, respectively. CONCLUSIONS: Based on the current Medicare Physician Fee Schedule, HRS is cost-effective at a willingness to pay threshold of $100,000. These results contain substantial uncertainty, suggesting more evidence is needed to refine future decision-making.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Levy JF, Khairnar R, Louie AV, et al. Evaluating the Cost-Effectiveness of Hydrogel Rectal Spacer in Prostate Cancer Radiation Therapy. Pract Radiat Oncol. 2018. PMID: 30342180. doi:10.1016/j.prro.2018.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。